Spero Therapeutics, a US-based biopharmaceutical company, has seen its shares plummet after announcing a deal with private equity firm KKR worth $105 million. The deal, which is expected to have implications for UK investors holding shares in the company, has contributed to a decline in Spero Therapeutics' share price on the London Stock Exchange.
According to data from the FTSE 100, Spero Therapeutics' shares have fallen by 15.6% in value over the past 24 hours, with the company's market capitalisation now standing at approximately $420 million. This decline is likely to have a ripple effect on the UK's financial markets, with investors holding shares in the company facing significant losses.
The deal between Spero Therapeutics and KKR is a significant development for the company, which has been working to develop novel treatments for rare bacterial infections. While the deal is expected to provide a much-needed boost to the company's finances, it has also led to concerns among investors over the impact on the company's share price.
For UK investors holding shares in Spero Therapeutics, the decline in share price is likely to have significant implications for their portfolios. With the company's shares now trading at a 12-month low, investors may be considering their options for managing their losses. As with any investment, it is essential for UK investors to seek advice from a qualified financial adviser to determine the best course of action.
The Bank of England has so far remained silent on the impact of the deal on the UK's financial markets. However, the central bank is likely to be monitoring the situation closely, particularly in light of the ongoing economic uncertainty surrounding the UK's exit from the European Union.